On Thursday, Following U.S. Stocks were among the “Top Gainers”: TherapeuticsMD, Inc. (NYSEMKT:TXMD), Zoe’s Kitchen, Inc. (NYSE:ZOES), Zogenix, Inc. (NASDAQ:ZGNX), Oncothyreon Inc (NASDAQ:ONTY)
TherapeuticsMD, Inc. (NYSEMKT:TXMD), with shares inclined 7.62%, closed at $5.65.
Zoe’s Kitchen Inc(NYSE:ZOES), with shares jumped 6.85%, settled at $34.94.
Zogenix, Inc. (NASDAQ:ZGNX), with shares climbed 6.56%, and closed at $1.30.
Oncothyreon Inc (USA)(NASDAQ:ONTY), surged 6.55%, and closed at $1.79.
Latest NEWS regarding these Stocks are depicted underneath:
TherapeuticsMD, Inc. (NYSEMKT:TXMD)
On March 10, TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare corporation, declared its fourth quarter and full-year financial results for the period ending Dec. 31, 2014.
Summary of 2014 financial results:
For the year ended Dec. 31, 2014, net proceed was about $15.0 million contrast with about $8.8 million for the preceding year. Proceed for the fourth quarter of 2014 was about $4.3 million contrast with about $2.9 million in the preceding year’s quarter, an raise of about 49 percent. Proceed growth during the fourth quarter and full-year of 2014 was primarily driven by raised sales of the corporation’s prenatal vitamin products, counting the launch of new products and volume growth of existing products.
Cost of goods sold raised to about $3.7 million for the full-year 2014 contrast with about $2.0 million for the preceding year.
Total operating expenses for the fourth quarter of 2014 and full-year ended Dec. 31, 2014, comprised of research and development (R&D) expenses and sales, general and administrative expenses (SG&A). R&D expenses for the full-year 2014 were about $43.2 million contrast with about $13.6 million for 2013, reflecting the corporation’s investment in two ongoing phase 3 clinical trials for its novel hormone therapy products in development. R&D expenses in the fourth quarter of 2014 were about $14.2 million contrast with about $5.8 million in the preceding year’s quarter, primarily due to the addition of a second phase 3 trial to support the corporation’s pipeline. SG&A expenses for the full-year 2014 were about $22.1 million contrast with about $19.0 million for 2013. SG&A expenses in the fourth quarter of 2014 were about $5.5 million contrast with about $4.6 million for the fourth quarter of 2013.
Non-operating revenue for the full-year 2014 comprised of miscellaneous and interest revenue of about $84,000, offset by financing costs of about $260,000.
Net operating loss for the full-year 2014 was about $54.2 million or $0.36 per basic and diluted share, contrast with about $28.4 million or $0.22 per basic and diluted share for 2013. Net operating loss in the fourth quarter of 2014 was about $16.3 million or $0.10 per basic and diluted share, contrast with about $8.4 million or $0.06 per basic and diluted share for 2013.
At Dec. 31, 2014, TherapeuticsMD had cash on hand of about $51.4 million, contrast with about $54.2 million at Dec. 31, 2013. In February 2015, the corporation accomplished a public offering of shares of its ordinary stock for net proceeds of about $59.1 million.
On the other hand, on March 9, an innovative women’s healthcare corporation, presented at the Endocrine Society’s 97th annual meeting new data showing healthcare providers’ visual assessments of vulvar and vaginal atrophy (VVA) before and after treatment with the investigational drug TX-004HR in the VagiCap™ dosage form correlated with noteworthy changes in vaginal cellular response and pH in postmenopausal women with VVA.
TherapeuticsMD, Inc. operates as a women’s health care product corporation. The corporation manufactures and distributes branded and generic prescription prenatal vitamins, in addition to over-the-counter vitamins and cosmetics.
Zoe’s Kitchen, Inc. (NYSE:ZOES)
Zoe’s Kitchen, Inc. (ZOES), stated financial results for the twelve and fifty-two weeks ended December 29, 2014.
Highlights for the twelve weeks ended December 29, 2014 as contrast to the twelve weeks ended December 30, 2013:
- Total proceed raised 39.5% to $40.0 million.
- Comparable restaurant sales raised 7.8%.
- Opened six Corporation-owned restaurants and attaind three franchise restaurants.
- Restaurant contribution raised 43.3% to $7.4 million.
- Adjusted EBITDA* raised 119.7% to $2.8 million.
- Net loss was $1.6 million, or $0.08 per basic and diluted share, for the twelve weeks ended December 29, 2014, contrast to net loss of $3.1 million, or $0.25 per basic and diluted share, for the twelve weeks ended December 30, 2013.
- Adjusted net loss* was $0.7 million, or $0.03 per basic and diluted share, for the twelve weeks ended December 29, 2014, contrast to adjusted net loss of $1.3 million or $0.06 per basic and diluted share, for the twelve weeks ended December 30, 2013.
Highlights for the fifty-two weeks ended December 29, 2014 as contrast to the fifty-two weeks ended December 30, 2013:
- Total proceed raised 47.6% to $171.7 million.
- Comparable restaurant sales raised 6.7%.
- Opened 30 Corporation-owned restaurants and attained five franchise restaurants.
- Restaurant contribution raised 48.1% to $34.2 million.
- Adjusted EBITDA* raised 46.8% to $16.0 million.
- Net loss was $10.0 million, or $0.58 per basic and diluted share, for the fifty-two weeks ended December 29, 2014, contrast to net loss of $3.7 million, or $0.30 per basic and diluted share, for the fifty-two weeks ended December 30, 2013.
- Adjusted net revenue* was $0.4 million, or $0.02 per diluted share, for the fifty-two weeks ended December 29, 2014, contrast to adjusted net loss of $0.4 million or $0.02 per diluted share, for the fifty-two weeks ended December 30, 2013.
2014 Fiscal Year Financial Results:
Total proceed, which comprises restaurant sales from Corporation-owned restaurants and royalty fees, raised 47.6% to $171.7 million in the fifty-two weeks ended December 29, 2014, from $116.4 million in the fifty-two weeks ended December 30, 2013. Restaurant sales for the fifty-two weeks ended December 29, 2014 were $171.3 million, an raise of 48.0% from the fifty-two weeks ended December 30, 2013.
Comparable restaurant sales raised 6.7% during the fifty-two weeks ended December 29, 2014, comprising of a 2.6% raise in transactions and a 2.6% raise in product mix, combined with a 1.5% rise in price. The comparable restaurant base comprises those restaurants open for 18 periods or longer and comprised of 81 restaurants as of December 29, 2014.
Restaurant contribution raised 48.1% to $34.2 million in the fifty-two weeks ended December 29, 2014, from $23.1 million in the fifty-two weeks ended December 30, 2013. As a percentage of restaurant sales, restaurant contribution was flat at 20.0% as the Corporation practiced higher commodity pricing driven by beef and poultry, offset by the leverage of strong comparable restaurant sales coupled with improvements in labor.
Net loss for the fifty-two weeks ended December 29, 2014 was $10.0 million, or $0.58 per basic and diluted share, contrast to a net loss of $3.7 million, or $0.30 per basic and diluted share, for the fifty-two weeks ended December 30, 2013.
Adjusted net revenue was $0.4 million, or $0.02 per diluted share, for the fifty-two weeks ended December 29, 2014, contrast to adjusted net loss of $0.4 million or $0.02 per diluted share, for the fifty-two weeks ended December 30, 2013.
Founded in 1995, Zoës Kitchen is a fast casual restaurant concept serving a distinct menu of fresh, wholesome, Mediterranean-inspired dishes delivered with Southern hospitality. With 139 locations in 15 states across the United States, Zoës Kitchen aims to deliver goodness to its customers by providing simple, tasty and fresh Mediterranean meals, inspired by family recipes, and made from scratch daily.
Zogenix, Inc. (NASDAQ:ZGNX)
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical corporation developing and commercializing products for the treatment of central nervous system (CNS) disorders, declared recently that it has reached a definitive contract to sell its Zohydro(R) ER (hydrocodone bitartrate) business to Pernix Therapeutics (PTX) for $100 million plus regulatory and sales milestones up to $283.5 million. Both companies plan to transition the Zogenix sales team and other select employees to Pernix.
This transaction enables Zogenix to plannedally shift focus to its late-stage CNS clinical pipeline highlighted by two promising product candidates:
- ZX008, which has orphan drug designation in the US and EU for the treatment of Dravet syndrome and is predictable to enter Phase 3 development this year, and;
- Relday, a unique long-acting injectable formulation of risperidone for the maintenance treatment of schizophrenia that is predictable to be ready for Phase 3 studies in the first half of 2016.
The sale of Zohydro ER to Pernix significantly reduces operating expenses, eliminates all R&D expenses related to ongoing abuse-deterrent formulations, and further enhances the Corporation’s financial strength with non-dilutive capital.
Terms of the contract:
Under terms of the contract, at closing, Pernix will pay Zogenix $30 million in cash, $20 million in ordinary stock and provide a $50 million short-term promissory note. Ten percent of the cash consideration will be deposited into escrow to fund potential indemnification claims for a period of 12 months, plus up to an additional $7 million to be deposited into escrow upon repayment of the promissory note. The Corporation is also eligible to receive $12.5 million upon approval of ZX007, a tablet formulation of extended-release hydrocodone with abuse-deterrent properties which is presently in development in partnership with Altus Formulation. In addition, Zogenix is eligible to receive cash payments of up to $271 million based on the achievement of pre-determined annual product sales milestones for Zohydro ER and ZX007. Pernix will also purchase a pre-defined amount of Zohydro ER product inventory.
The Zohydro ER NDA and related investigational new drug applications will be transferred to Pernix right away upon closing and Pernix will assume responsibility for Zogenix’s royalty and manufacturing obligations to Daravita Limited, an indirect wholly-owned partner of Alkermes plc. Upon closing, Pernix will also assume regulatory and financial responsibility for the ongoing efforts related to amending the Zohydro ER label to comprise abuse-deterrent claims and for the development of ZX007, with Zogenix providing assistance in the development of both programs under a Transitional Services Contract for up to 18 months following closing. The transaction is predictable to close in April 2015, subject to customary closing conditions.
Leerink Partners LLC acted as financial advisor and Latham & Watkins LLP acted as legal advisor to Zogenix on the transaction.
Zogenix, Inc. (ZGNX) is a pharmaceutical corporation committed to developing and commercializing therapies that address specific clinical needs for people living with pain-related conditions and CNS disorders who need innovative treatment alternatives to assist them return to normal daily functioning.
Oncothyreon Inc (NASDAQ:ONTY)
Oncothyreon Inc (ONTY), stated financial results for the year and quarter ended December 31, 2014.
Net loss for the year ended December 31, 2014 was $50.0 million, or $0.64 per basic and diluted share, contrast with a net loss of $38.8 million, or $0.62 per basic and diluted share, for the comparable period in 2013. The rise in net loss was due to higher research and development expenses, primarily as a result of an raise of $10.0 million in license fees paid to Array. The rise in net loss was also the result of higher general and administrative expenses and lower non-cash revenue from the change in fair value of warrant liability, which was $0.8 million for the year ended December 31, 2014 contrast to $2.3 million for the year ended December 31, 2013.
Net loss for the three months ended December 31, 2014 was $27.6 million, or $0.30 per basic and diluted share, contrast with a net loss of $6.4 million, or $0.09 per basic and diluted share, for the comparable period in 2013. The rise in net loss for the three months ended December 31, 2014 contrast to the preceding year period was primarily attributable to an upfront payment of $20.0 million to Array in December 2014 and lower non-cash revenue from the change in the fair value of warrant liability, which was $0.3 million for the three months ended December 31, 2014 contrast to $1.2 million for the three months ended December 31, 2013.
As of December 31, 2014, Oncothyreon’s cash, cash equivalents and investments were $63.7 million, contrast to $72.6 million at December 31, 2013, a decrease of $8.9 million, or 12.3 percent. The decrease was primarily attributable to $48.4 million of cash used in operations during the year ended December 31, 2014, partially offset by the net proceeds of $40.2 million from the closing of concurrent but separate underwritten offerings of Oncothyreon ordinary stock and Series A convertible preferred stock in September 2014.
In February 2015, Oncothyreon closed additional concurrent but separate underwritten offerings of Oncothyreon ordinary stock and Series B convertible preferred stock, resulting in net proceeds of 22.4 million.
Financial Guidance:
Oncothyreon believes the following financial guidance to be correct as of the date offered. Oncothyreon is providing this guidance as a convenience to investors and assumes no obligation to update it.
Oncothyreon presently anticipates operating expenses in 2015 to be lower than in 2014, which comprised of the upfront payment to Array for the exclusive license to ONT-380. Oncothyreon presently anticipates cash used in operations in 2015 to be about $35.0 - $38.0 million.
Oncothyreon Inc, a clinical-stage biopharmaceutical corporation, develops therapeutic products for the treatment of cancer. Its product candidate comprises Tecemotide, a vaccine for the treatment of non-small cell lung cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
